Cargando…

Response to: Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”

Detalles Bibliográficos
Autores principales:	Rai, Nabham, Veeroju, Swathi, Schymura, Yves, Janssen, Wiebke, Wietelmann, Astrid, Kojonazarov, Baktybek, Weissmann, Norbert, Stasch, Johannes-Peter, Ghofrani, Hossein Ardeschir, Seeger, Werner, Schermuly, Ralph Theo, Novoyatleva, Tatyana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311298/ https://www.ncbi.nlm.nih.gov/pubmed/30643819 http://dx.doi.org/10.1155/2018/7491284

Ejemplares similares

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding
por: Rai, Nabham, et al.
Publicado: (2018)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension
por: Rai, Nabham, et al.
Publicado: (2022)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
por: Janssen, Wiebke, et al.
Publicado: (2015)

Effect of p53 activation on experimental right ventricular hypertrophy
por: Veeroju, Swathi, et al.
Publicado: (2020)

Improvement of right heart structure and function by BAY 41-8543 in pulmonary artery banded mice
por: Janssen, Wiebke, et al.
Publicado: (2011)

Correction: Improvement of right heart structure and function by BAY41-8543 in pulmonary artery banded mice
por: Janssen, Wiebke, et al.
Publicado: (2011)

Retraction: Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis
por: Boehm, Mario, et al.
Publicado: (2022)

IRAG1 Deficient Mice Develop PKG1β Dependent Pulmonary Hypertension
por: Biswas, Siladitta, et al.
Publicado: (2020)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle
por: Luitel, Himal, et al.
Publicado: (2017)

A novel noninvasive method for estimating right ventricular systolic pressure in rodents with pulmonary artery banding
por: Kojonazarov, Baktybek, et al.
Publicado: (2023)

Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2021)

Author Correction: Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2022)

Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice
por: Sydykov, Akylbek, et al.
Publicado: (2020)

Genetic Delivery and Gene Therapy in Pulmonary Hypertension
por: Rai, Nabham, et al.
Publicado: (2021)

Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling
por: Kojonazarov, Baktybek, et al.
Publicado: (2013)

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2018)

Correction to: Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2022)

Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension
por: Amirjanians, Matthieu, et al.
Publicado: (2017)

Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Andersen, Asger
Publicado: (2018)

Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction
por: Novoyatleva, Tatyana, et al.
Publicado: (2013)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing
por: Esfandiary, Azadeh, et al.
Publicado: (2019)

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension
por: Kosanovic, Djuro, et al.
Publicado: (2011)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4)
por: Lu, Shun, et al.
Publicado: (2017)

Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
por: Seimetz, Michael, et al.
Publicado: (2015)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching
por: Chamorro, Virginia, et al.
Publicado: (2018)

Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling
por: Tian, Xia, et al.
Publicado: (2011)

Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties
por: Luitel, Himal, et al.
Publicado: (2020)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

sGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
por: Egemnazarov, Bakytbek, et al.
Publicado: (2009)

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
por: Pullamsetti, Soni, et al.
Publicado: (2005)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction
por: Veith, Christine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cqg1gpnium28gd5iel74qa1lst